Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emergency research rules should not require disclosure of study data, attorney says.

This article was originally published in The Gray Sheet

Executive Summary

PUBLIC DISCLOSURE OF EMERGENCY RESEARCH SHOULD BE ELIMINATED as a requirement in FDA's proposed policy on waiver of informed consent in emergency research, Jeffrey Gibbs, of the Washington, D.C. law firm Hyman, Phelps and McNamara, argues in Nov. 6 written comments to the agency. Calling for FDA to "delete" the proposed requirement for public disclosure of emergency research involving the waivers, Gibbs says that "clinical studies have historically been confidential" with "no regulatory requirement that communities be notified."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel